Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 90 entries
Sorted by: Best Match Show Resources per page
30th anniversary.

European journal of drug metabolism and pharmacokinetics

Benakis A.
PMID: 16010856
Eur J Drug Metab Pharmacokinet. 2005 Jan-Jun;30(1):1-2. doi: 10.1007/BF03226402.

No abstract available.

Cite
Benakis A. 30th anniversary. Eur J Drug Metab Pharmacokinet. 2005;30(1):1-2doi: 10.1007/BF03226402.
Benakis, A. (2005). 30th anniversary. European journal of drug metabolism and pharmacokinetics, 30(1), 1-2. https://doi.org/10.1007/BF03226402
Benakis, A. "30th anniversary." European journal of drug metabolism and pharmacokinetics vol. 30,1 (2005): 1-2. doi: https://doi.org/10.1007/BF03226402
Benakis A. 30th anniversary. Eur J Drug Metab Pharmacokinet. 2005 Jan-Jun;30(1):1-2. doi: 10.1007/BF03226402. PMID: 16010856.
Copy Download .nbib Format: NLM
A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.

European journal of drug metabolism and pharmacokinetics

Vonk MC, Guillén-Del-Castillo A, Kreuter M, Avis M, Marzin K, Mack SR, Wind S, Gahlemann M.
PMID: 34664183
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):81-89. doi: 10.1007/s13318-021-00728-7. Epub 2021 Oct 18.

BACKGROUND AND OBJECTIVES: Nintedanib is a tyrosine kinase inhibitor approved for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD), idiopathic pulmonary fibrosis, and other chronic fibrosing ILDs with a progressive phenotype. As nintedanib may cause foetal harm, patients...

Cite
Vonk MC, Guillén-Del-Castillo A, Kreuter M, et al. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. Eur J Drug Metab Pharmacokinet. 2021;47(1):81-89doi: 10.1007/s13318-021-00728-7.
Vonk, M. C., Guillén-Del-Castillo, A., Kreuter, M., Avis, M., Marzin, K., Mack, S. R., Wind, S., & Gahlemann, M. (2022). A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. European journal of drug metabolism and pharmacokinetics, 47(1), 81-89. https://doi.org/10.1007/s13318-021-00728-7
Vonk, Madelon C, et al. "A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease." European journal of drug metabolism and pharmacokinetics vol. 47,1 (2022): 81-89. doi: https://doi.org/10.1007/s13318-021-00728-7
Vonk MC, Guillén-Del-Castillo A, Kreuter M, Avis M, Marzin K, Mack SR, Wind S, Gahlemann M. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):81-89. doi: 10.1007/s13318-021-00728-7. Epub 2021 Oct 18. PMID: 34664183.
Copy Download .nbib Format: NLM
Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review.

European journal of drug metabolism and pharmacokinetics

Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E.
PMID: 34687440
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):1-18. doi: 10.1007/s13318-021-00731-y. Epub 2021 Oct 23.

Flavonoids are phytochemicals that are well known for their beneficial pharmacological properties. Diosmin is a flavone glycoside derived from hesperidin, a flavanone abundantly found in citrus fruits. Daflon is an oral phlebotonic flavonoid combination containing diosmin and hesperidin (9:1)...

Cite
Gerges SH, Wahdan SA, Elsherbiny DA, et al. Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review. Eur J Drug Metab Pharmacokinet. 2021;47(1):1-18doi: 10.1007/s13318-021-00731-y.
Gerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El-Demerdash, E. (2022). Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review. European journal of drug metabolism and pharmacokinetics, 47(1), 1-18. https://doi.org/10.1007/s13318-021-00731-y
Gerges, Samar H, et al. "Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review." European journal of drug metabolism and pharmacokinetics vol. 47,1 (2022): 1-18. doi: https://doi.org/10.1007/s13318-021-00731-y
Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):1-18. doi: 10.1007/s13318-021-00731-y. Epub 2021 Oct 23. PMID: 34687440.
Copy Download .nbib Format: NLM
Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.

European journal of drug metabolism and pharmacokinetics

Kareva I, Zutshi A, Mateo CV, Papasouliotis O.
PMID: 34328632
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):601-611. doi: 10.1007/s13318-021-00706-z. Epub 2021 Jul 30.

Immunosuppressive drugs can alleviate debilitating symptoms of autoimmune diseases, but, by the same token, excessive immune suppression can result in an increased risk of infection. Despite the dangers of a compromised immune system, clear definitions of what constitutes excessive...

Cite
Kareva I, Zutshi A, Mateo CV, et al. Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data. Eur J Drug Metab Pharmacokinet. 2021;46(5):601-611doi: 10.1007/s13318-021-00706-z.
Kareva, I., Zutshi, A., Mateo, C. V., & Papasouliotis, O. (2021). Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data. European journal of drug metabolism and pharmacokinetics, 46(5), 601-611. https://doi.org/10.1007/s13318-021-00706-z
Kareva, Irina, et al. "Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data." European journal of drug metabolism and pharmacokinetics vol. 46,5 (2021): 601-611. doi: https://doi.org/10.1007/s13318-021-00706-z
Kareva I, Zutshi A, Mateo CV, Papasouliotis O. Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):601-611. doi: 10.1007/s13318-021-00706-z. Epub 2021 Jul 30. PMID: 34328632; PMCID: PMC8478771.
Copy Download .nbib Format: NLM
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.

European journal of drug metabolism and pharmacokinetics

Desch M, Wunderlich G, Goettel M, Goetz S, Liesenfeld KH, Chan TS, Rosenbrock H, Sennewald R, Link J, Keller S, Wind S.
PMID: 34716565
Eur J Drug Metab Pharmacokinet. 2021 Oct 29; doi: 10.1007/s13318-021-00723-y. Epub 2021 Oct 29.

BACKGROUND AND OBJECTIVE: Increased glycine availability at the synaptic cleft may enhance N-methyl-D-aspartate receptor signalling and provide a promising therapeutic strategy for cognitive impairment associated with schizophrenia. These studies aimed to assess the pharmacokinetics of BI 425809, a potent...

Cite
Desch M, Wunderlich G, Goettel M, et al. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. Eur J Drug Metab Pharmacokinet. 2021;doi: 10.1007/s13318-021-00723-y.
Desch, M., Wunderlich, G., Goettel, M., Goetz, S., Liesenfeld, K. H., Chan, T. S., Rosenbrock, H., Sennewald, R., Link, J., Keller, S., & Wind, S. (2021). Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. European journal of drug metabolism and pharmacokinetics, . https://doi.org/10.1007/s13318-021-00723-y
Desch, Michael, et al. "Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor." European journal of drug metabolism and pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s13318-021-00723-y
Desch M, Wunderlich G, Goettel M, Goetz S, Liesenfeld KH, Chan TS, Rosenbrock H, Sennewald R, Link J, Keller S, Wind S. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. Eur J Drug Metab Pharmacokinet. 2021 Oct 29; doi: 10.1007/s13318-021-00723-y. Epub 2021 Oct 29. PMID: 34716565.
Copy Download .nbib Format: NLM
Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.

European journal of drug metabolism and pharmacokinetics

Sridharan K, Abbasi MY, Mulubwa M.
PMID: 34156647
Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):539-546. doi: 10.1007/s13318-021-00695-z. Epub 2021 Jun 22.

BACKGROUND AND OBJECTIVE: Critically ill children may exhibit varied vancomycin pharmacokinetic parameters mainly due to altered protein binding, extracellular volume, and renal elimination. The objective of this study was to assess the pharmacokinetics of vancomycin in critically ill children...

Cite
Sridharan K, Abbasi MY, Mulubwa M. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children. Eur J Drug Metab Pharmacokinet. 2021;46(4):539-546doi: 10.1007/s13318-021-00695-z.
Sridharan, K., Abbasi, M. Y., & Mulubwa, M. (2021). Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children. European journal of drug metabolism and pharmacokinetics, 46(4), 539-546. https://doi.org/10.1007/s13318-021-00695-z
Sridharan, Kannan, et al. "Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children." European journal of drug metabolism and pharmacokinetics vol. 46,4 (2021): 539-546. doi: https://doi.org/10.1007/s13318-021-00695-z
Sridharan K, Abbasi MY, Mulubwa M. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children. Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):539-546. doi: 10.1007/s13318-021-00695-z. Epub 2021 Jun 22. PMID: 34156647.
Copy Download .nbib Format: NLM
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.

European journal of drug metabolism and pharmacokinetics

Desch M, Wunderlich G, Goettel M, Goetz S, Liesenfeld KH, Chan TS, Rosenbrock H, Sennewald R, Link J, Keller S, Wind S.
PMID: 34716565
Eur J Drug Metab Pharmacokinet. 2021 Oct 29; doi: 10.1007/s13318-021-00723-y. Epub 2021 Oct 29.

BACKGROUND AND OBJECTIVE: Increased glycine availability at the synaptic cleft may enhance N-methyl-D-aspartate receptor signalling and provide a promising therapeutic strategy for cognitive impairment associated with schizophrenia. These studies aimed to assess the pharmacokinetics of BI 425809, a potent...

Cite
Desch M, Wunderlich G, Goettel M, et al. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. Eur J Drug Metab Pharmacokinet. 2021;doi: 10.1007/s13318-021-00723-y.
Desch, M., Wunderlich, G., Goettel, M., Goetz, S., Liesenfeld, K. H., Chan, T. S., Rosenbrock, H., Sennewald, R., Link, J., Keller, S., & Wind, S. (2021). Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. European journal of drug metabolism and pharmacokinetics, . https://doi.org/10.1007/s13318-021-00723-y
Desch, Michael, et al. "Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor." European journal of drug metabolism and pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s13318-021-00723-y
Desch M, Wunderlich G, Goettel M, Goetz S, Liesenfeld KH, Chan TS, Rosenbrock H, Sennewald R, Link J, Keller S, Wind S. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. Eur J Drug Metab Pharmacokinet. 2021 Oct 29; doi: 10.1007/s13318-021-00723-y. Epub 2021 Oct 29. PMID: 34716565.
Copy Download .nbib Format: NLM
Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers.

European journal of drug metabolism and pharmacokinetics

Liang D, Shen J, Jia Y, Dai M, Li X, Zhou L, Wang W, Yang B, Shao J, Jiang Y, Xie H, Sun H.
PMID: 34549388
Eur J Drug Metab Pharmacokinet. 2021 Nov;46(6):793-805. doi: 10.1007/s13318-021-00718-9. Epub 2021 Sep 21.

BACKGROUND AND OBJECTIVES: As a chiral drug, oxiracetam (ORT) can exist in two different isomeric forms: S-oxiracetam (S-ORT) and R-oxiracetam (R-ORT). S-ORT has emerged as a promising nootropic drug with the potential to treat brain injury and the resulting...

Cite
Liang D, Shen J, Jia Y, et al. Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2021;46(6):793-805doi: 10.1007/s13318-021-00718-9.
Liang, D., Shen, J., Jia, Y., Dai, M., Li, X., Zhou, L., Wang, W., Yang, B., Shao, J., Jiang, Y., Xie, H., & Sun, H. (2021). Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers. European journal of drug metabolism and pharmacokinetics, 46(6), 793-805. https://doi.org/10.1007/s13318-021-00718-9
Liang, Dahu, et al. "Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers." European journal of drug metabolism and pharmacokinetics vol. 46,6 (2021): 793-805. doi: https://doi.org/10.1007/s13318-021-00718-9
Liang D, Shen J, Jia Y, Dai M, Li X, Zhou L, Wang W, Yang B, Shao J, Jiang Y, Xie H, Sun H. Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2021 Nov;46(6):793-805. doi: 10.1007/s13318-021-00718-9. Epub 2021 Sep 21. PMID: 34549388.
Copy Download .nbib Format: NLM
Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations.

European journal of drug metabolism and pharmacokinetics

Belveyre T, Scala-Bertola J, Esposito M, Luc A, Lipman J, Novy E.
PMID: 33959888
Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):479-485. doi: 10.1007/s13318-021-00688-y. Epub 2021 May 06.

BACKGROUND AND OBJECTIVES: A high inter-individual variability in pharmacokinetic parameters in obese patients is observed. The objective of this study was to evaluate the effect of obesity parameters on the pharmacokinetics of cefoxitin administered for antibiotic prophylaxis during bariatric...

Cite
Belveyre T, Scala-Bertola J, Esposito M, et al. Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations. Eur J Drug Metab Pharmacokinet. 2021;46(4):479-485doi: 10.1007/s13318-021-00688-y.
Belveyre, T., Scala-Bertola, J., Esposito, M., Luc, A., Lipman, J., & Novy, E. (2021). Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations. European journal of drug metabolism and pharmacokinetics, 46(4), 479-485. https://doi.org/10.1007/s13318-021-00688-y
Belveyre, Thibaut, et al. "Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations." European journal of drug metabolism and pharmacokinetics vol. 46,4 (2021): 479-485. doi: https://doi.org/10.1007/s13318-021-00688-y
Belveyre T, Scala-Bertola J, Esposito M, Luc A, Lipman J, Novy E. Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations. Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):479-485. doi: 10.1007/s13318-021-00688-y. Epub 2021 May 06. PMID: 33959888.
Copy Download .nbib Format: NLM
Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats.

European journal of drug metabolism and pharmacokinetics

Cui M, Zhu F, Yin Y, Sui Y, Yan X, Chen T.
PMID: 34855161
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):117-126. doi: 10.1007/s13318-021-00738-5. Epub 2021 Dec 02.

BACKGROUND AND OBJECTIVES: Gegenqinlian decoction (GQD), a classic traditional Chinese medicine (TCM), was described in Shanghan Lun. GQD is often combined with antihyperlipidemic drugs (mainly atrovastatin calcium) in TCM clinics. However, the herb-drug interaction between GQD and atrovastatin calcium...

Cite
Cui M, Zhu F, Yin Y, et al. Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats. Eur J Drug Metab Pharmacokinet. 2021;47(1):117-126doi: 10.1007/s13318-021-00738-5.
Cui, M., Zhu, F., Yin, Y., Sui, Y., Yan, X., & Chen, T. (2022). Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats. European journal of drug metabolism and pharmacokinetics, 47(1), 117-126. https://doi.org/10.1007/s13318-021-00738-5
Cui, Mingyu, et al. "Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats." European journal of drug metabolism and pharmacokinetics vol. 47,1 (2022): 117-126. doi: https://doi.org/10.1007/s13318-021-00738-5
Cui M, Zhu F, Yin Y, Sui Y, Yan X, Chen T. Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):117-126. doi: 10.1007/s13318-021-00738-5. Epub 2021 Dec 02. PMID: 34855161.
Copy Download .nbib Format: NLM
Pharmacokinetics and Pharmacodynamics of Huanglian-Houpo Decoction Based on Berberine Hydrochloride and Magnolol Against H1N1 Influenza Virus.

European journal of drug metabolism and pharmacokinetics

Zhang FL, Yin XJ, Yan YL, Wu QF.
PMID: 34635990
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):57-67. doi: 10.1007/s13318-021-00724-x. Epub 2021 Oct 12.

BACKGROUND AND OBJECTIVES: Huanglian-Houpo decoction (HH), which is recorded in the famous traditional Chinese medicine monograph "Puji Fang," contains two individual herbs, Huanglian (Rhizoma coptidis) and Houpo (Magnoliae officinalis cortex). It was regularly used to treat seasonal epidemic colds...

Cite
Zhang FL, Yin XJ, Yan YL, et al. Pharmacokinetics and Pharmacodynamics of Huanglian-Houpo Decoction Based on Berberine Hydrochloride and Magnolol Against H1N1 Influenza Virus. Eur J Drug Metab Pharmacokinet. 2021;47(1):57-67doi: 10.1007/s13318-021-00724-x.
Zhang, F. L., Yin, X. J., Yan, Y. L., & Wu, Q. F. (2022). Pharmacokinetics and Pharmacodynamics of Huanglian-Houpo Decoction Based on Berberine Hydrochloride and Magnolol Against H1N1 Influenza Virus. European journal of drug metabolism and pharmacokinetics, 47(1), 57-67. https://doi.org/10.1007/s13318-021-00724-x
Zhang, Feng-Ling, et al. "Pharmacokinetics and Pharmacodynamics of Huanglian-Houpo Decoction Based on Berberine Hydrochloride and Magnolol Against H1N1 Influenza Virus." European journal of drug metabolism and pharmacokinetics vol. 47,1 (2022): 57-67. doi: https://doi.org/10.1007/s13318-021-00724-x
Zhang FL, Yin XJ, Yan YL, Wu QF. Pharmacokinetics and Pharmacodynamics of Huanglian-Houpo Decoction Based on Berberine Hydrochloride and Magnolol Against H1N1 Influenza Virus. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):57-67. doi: 10.1007/s13318-021-00724-x. Epub 2021 Oct 12. PMID: 34635990; PMCID: PMC8505218.
Copy Download .nbib Format: NLM
Correction to: The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.

European journal of drug metabolism and pharmacokinetics

Zang YN, Dong F, Li AN, Wang CY, Guo GX, Wang Q, Zhang YF, Zhang L, de Leon J, Ruan CJ.
PMID: 33743172
Eur J Drug Metab Pharmacokinet. 2021 May;46(3):373-374. doi: 10.1007/s13318-021-00680-6.

No abstract available.

Cite
Zang YN, Dong F, Li AN, et al. Correction to: The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. Eur J Drug Metab Pharmacokinet. 2021;46(3):373-374doi: 10.1007/s13318-021-00680-6.
Zang, Y. N., Dong, F., Li, A. N., Wang, C. Y., Guo, G. X., Wang, Q., Zhang, Y. F., Zhang, L., de Leon, J., & Ruan, C. J. (2021). Correction to: The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. European journal of drug metabolism and pharmacokinetics, 46(3), 373-374. https://doi.org/10.1007/s13318-021-00680-6
Zang, Yan-Nan, et al. "Correction to: The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients." European journal of drug metabolism and pharmacokinetics vol. 46,3 (2021): 373-374. doi: https://doi.org/10.1007/s13318-021-00680-6
Zang YN, Dong F, Li AN, Wang CY, Guo GX, Wang Q, Zhang YF, Zhang L, de Leon J, Ruan CJ. Correction to: The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. Eur J Drug Metab Pharmacokinet. 2021 May;46(3):373-374. doi: 10.1007/s13318-021-00680-6. PMID: 33743172.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 90 entries